Vertex Pharmaceuticals (VRTX) Exchanges $103.3M In Convertible Notes Into Common Stock
More News related to VRTX
- Morgan Stanley Upgrades Vertex (VRTX) to Overweight
- Analysts Mixed as Results from Trial of Vertex's Telaprevir Send the Stock Higher (VRTX)
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Morning Movers 11/02: CIT, HGSI, EAC, VRTX, CTB, BC, F Higher; YRCW, GTXI, FSNM, LDK Lower
- More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens
More News related to Equity Offerings
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) said holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for approximately 4.8 million shares of the Company's common stock, which is approximately 287,000 shares more than the number of shares into which the notes were convertible under their original terms.
Related Categories
Equity OfferingsStocks Mentioned
+0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
